Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-07-03
2007-07-03
Chernyshev, Olga N. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S040500, C435S040520, C436S501000, C436S503000, C436S547000, C436S063000, C530S326000, C530S387100, C530S402000, C530S403000
Reexamination Certificate
active
10244151
ABSTRACT:
A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.
REFERENCES:
patent: 6432636 (2002-08-01), Maresh et al.
Ailles, et al., “Induction of Perlecan Gene Expression Precedes Amyloid Formation During Experimental Murine AA Amyloidogenesis,” Laboratory Investigation, vol. 69, No. 4, pp. 443-448, 1993.
Cohen et al., “Structural Characterization of the Complete Human Perlecan Gene and its Promoter,” Proc. Natl. Acad. Sci USA, vol. 90, pp. 10404-10408, 1993.
Dolan et al., “Identification and Sites in Domain I of Perlecan That Regulate Heparan Sulfate Synthesis,” Journal of Bio. Chem, vol. 272, No. 7, pp. 4316-4322, Feb. 14, 1997.
Groffen, et al., “Expression and Characterization of Human Perlecan Domains I and II Synthesized by Baculovirus-infected Insect Cells,” European Journal of Biochem., vol. 241, pp. 827-834, 1996.
Murdoch et al., “Widespread Expression of Perlecan Proteoglycan in Basement Membranes and Extracellular Matrices of Human Tissues as Detected by a Novel Monoclonal Antibody Against Domain III and by In Situ Hybridization,” The Journal of Histochem. and Cytochem., vol. 42, No. 2, pp. 239-249, 1994.
Noonan et al., “Perlecan, the Large Low-density Proteoglycan of Basement Membranes: Structure and Variant Forms,” Kidney International, vol. 43, pp. 53-60, 1993.
Sigma Chemical Company, “Biochemicals Organic Compounds for Research and Diagnostic Reagents,” Sigma Chemical Company, 1992, pp. 513 (see products entitle heparan sulfate).
Stryer,Biochemsity, W.H. Freeman and Company, San Francisco, 1981, pp. 13-16 and 512-513.
Goedert et al., “Assembly of Microtubule-associated Protein Tau into Alzheimer-life Filaments Induced by Sulphated Glycosaminoglycans,” Nature, vol. 383, pp. 550-553, Oct. 1996.
Maresh et al., “Detection and Quantitation of Perlecan mRNA Levels in Alzheimer's Disease and Normal Aged Hippocampus by Competitive Reverse Transcription-Polymerase Chain Reaction,” J. Neurochem., vol. 67, No. 3, pp. 1132-1143, 1996.
Murdoch et al., “Primary Structure of the Human Heparan Sulfate Proteoglycan from Basement Membrane (HSPG2/Perlecan),” Journal of Bio. Chem., vol. 267, No. 12, pp. 8544-8557, Apr. 25, 1992.
Snow et al., “The Presence of Heparan Sulfate Proteoglycans in the Neuritic Plaques and Congophilic Angiopathy in Alzheimer's Disease,” American Journal of Pathology, vol. 133, No. 3, pp. 456-463, Dec. 1988.
Snow et al., “Immunolocalization of Heparan Sulfate Proteoglycans to the Prion Protein Amyloid Plaques of Gerstmann-Straussler Syndrome, Creutzfeldt-Jakob Disease and Scrapie,”Laboratory Investigation, vol. 63, No. 5, pp. 601-611, 1990.
Snow et al., “Proteoglycans in the Pathogenesis of Alzheimer's Disease and Other Amyloidoses,” Neurobiology of Aging, vol. 10, pp. 481-497, 1989.
Snow et al., “Heparan Sulfate Proteoglycans in Diffuse Plaques of Hippocampus but not of Cerebellum in Alzheimer's Disease Brain,” American Journal of Pathology, vol. 144, No. 2, pp. 337-347, Feb. 1994.
Snow et al., “Differential Binding of Vascular Cell-Derived Proteoglycans (Perlecan, Biglycan, Decorin, and Versican) to the Beta-Amyloid Protein of Alzheimer's Disease,” Archives of Biochemistry and Biophysics, vol. 320, No. 1, pp. 84-95, Jun. 20, 1995.
Brunden et al., “pH-Dependent Binding of Synthetic β-Amyloid Peptides in Glycosaminoglycans,” J. Neurochem., vol. 61, No. 6, pp. 2147-2154, 1993.
Snow et al., “An Important Role of Heparan Sulfate Proteoglycan (Perlecan) in a Model System for the Deposition and Persistence of Fibrillar Aβ-Amyloid in Rat Brain,” Neuron, vol. 12, pp. 219-234, Jan. 1994.
Gupta-Bansal et al., “Proteoglycan-Mediated Inhibition of Aβ Proteolysis,” Journal of Bio. Chem., vol. 270, No. 31, pp. 18666-18671, 1995.
Snow et al., “Early Accumulation of Heparan Sulfate in Neurons and in the Beta-Amyloid Protein-Containing Lesions of Alzheimer's Disease and Down's Syndrome,” American Journal of Pathology, vol. 137, No. 5, pp. 1253-1270, Nov. 1990.
Kallunki et al., “Human Basement Membrane Heparan Sulfate Proteoglycan Core Protein: A 467-kD Protein Containing Multiple Domains Resembling Elements of the Low Density Lipoprotein Receptor, Laminin, Neural Cell Adhesion Molecules, and Epidermal Growth Factor,” Journal of Cell Biology, vol. 116, pp. 559-571, 1992.
Noonan et al., “The Complete Sequence of Perlecan, a Basement Membrane Heparan Sulphate Proteoglycan, Reveals Extensive Similarity with Laminin A Chain, Low Density Lipoprotein-Receptor, and the Neural Cell Adhesion Molecule,” Journal of Bio. Chem., vol. 266, No. 34, pp. 22939-22947, Dec. 5, 1991.
Kato et al., “Basement Membrane Proteoglycan in Various Tissues: Characterization Using Monoclonal Antibodies to the Engelbreth-Holm-Swarm Mouse Tumor Low Density Heparan Sulfate Proteoglycan,” Journal of Cell Biology, pp. 2203-2210, Jun. 1988.
Kokenyesi et al., “Formation of Heparan Sulfate or Chondroitin/Dermatan Sulfate on Recombinant Domain I of Mouse Perlecan Expressed in Chinese Hamster Ovary Cells,” Biochemical and Biophysical Research Communications, vol. 211, No. 1, pp. 262-267, Jun. 6, 1995.
Nochlin et al., “A Simple Method of Rapid Freezing Adequately Preserves Brain Tissue for Immunocytochemistry Light and Electron Microscopic Examination,” Acta Neuropathol, vol. 86, pp. 645-650, 1993.
Jacob et al., “The 5′Splice Site: Phylogenetic Evolution and Variable Geometry of Association with U1RNA,” Nucleic Acids Research, vol. 17, No. 6, pp. 2159-2180, 1989.
Jackson et al., “A Reappraisal of Non-Consensus mRNA Splice Sites,” Nucleic Acids Research, vol. 19, No. 14, pp. 3795-3798, 1991.
Merrifield, “Solid Phase Synthesis,”Science, vol. 232, pp. 341-347, Apr. 18, 1986.
Fields et al., “Solid Phase Peptide Synthesis Utilizing 9-Fluorenylmethoxycarbonyl Amino Acids,” Intl. J. Peptide Protein Res., vol. 35, pp. 161-214, 1990.
Hampson et al., “Separation of Radiolabelled Glycosaminoglycan Oligosaccharides by Polyacrylamide-Gel Electrophoresis,” vol. 221, pp. 697-705, 1984.
Farach-Carson et al., “Extraction and Isolation of Glycoproteins and Proteoglycans,” BioTechniques, vol. 7, No. 5, pp. 482-493, 1989.
Hovingh et al., “Differentially Expressed Patterns of Glycosaminoglycan Structure in Heparan Sulfate Proteoglycans and Free Chains,” Eur. J. Biochem., vol. 211, pp. 771-779, 1993.
Maresh Grace
Snow Alan D.
Chernyshev Olga N.
Dwyer Patrick M.
LandOfFree
Therapeutic and diagnostic applications of perlecan domain I... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic applications of perlecan domain I..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic applications of perlecan domain I... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803833